IL297771A - Leriglitazone for treating lung inflammation and interstitial lung disease - Google Patents

Leriglitazone for treating lung inflammation and interstitial lung disease

Info

Publication number
IL297771A
IL297771A IL297771A IL29777122A IL297771A IL 297771 A IL297771 A IL 297771A IL 297771 A IL297771 A IL 297771A IL 29777122 A IL29777122 A IL 29777122A IL 297771 A IL297771 A IL 297771A
Authority
IL
Israel
Prior art keywords
ethoxy
phenyl
methyl
thiazolidine
dione
Prior art date
Application number
IL297771A
Other languages
English (en)
Hebrew (he)
Inventor
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Saura Anna Vilalta
L?Pez Estefania Traver
Poli Sonia Maria
Useros Nuria Izquierdo
Original Assignee
Minoryx Therapeutics S L
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Saura Anna Vilalta
L?Pez Estefania Traver
Poli Sonia Maria
Useros Nuria Izquierdo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L, Pedemonte Marc Martinell, Lalanza Maria Pilar Pizcueta, Saura Anna Vilalta, L?Pez Estefania Traver, Poli Sonia Maria, Useros Nuria Izquierdo filed Critical Minoryx Therapeutics S L
Publication of IL297771A publication Critical patent/IL297771A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL297771A 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease IL297771A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382356 2020-04-30
PCT/IB2021/053651 WO2021220250A1 (en) 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease

Publications (1)

Publication Number Publication Date
IL297771A true IL297771A (en) 2022-12-01

Family

ID=70779625

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297771A IL297771A (en) 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease

Country Status (11)

Country Link
US (1) US20230172921A1 (https=)
EP (1) EP4142720A1 (https=)
JP (1) JP2023525981A (https=)
KR (1) KR20230035522A (https=)
CN (1) CN116390725A (https=)
AU (1) AU2021265345A1 (https=)
BR (1) BR112022021951A2 (https=)
CA (1) CA3180351A1 (https=)
IL (1) IL297771A (https=)
MX (1) MX2022013021A (https=)
WO (1) WO2021220250A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4642456A1 (en) * 2022-12-28 2025-11-05 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590774A (en) * 2008-08-07 2012-09-28 Pulmagen Therapeutics Inflammation Ltd Substantially pure 5R enantiomers of pioglitazone and rosiglitazone for treating inflammatory respiratory diseases
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
WO2011047048A1 (en) * 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
WO2011073662A1 (en) * 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
EA202091120A3 (ru) 2014-04-02 2020-12-30 Минорикс Терапьютикс С.Л. Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
JP7040798B2 (ja) * 2016-12-01 2022-03-23 ミノリックス セラピューティクス エセ．エレ． 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン
CN112823004A (zh) * 2018-06-06 2021-05-18 米尼奥尔克斯治疗有限公司 5-[[4-[2-[5-乙酰基吡啶-2-基]乙氧基]苄基]-1,3-噻唑烷-2,4-二酮及其盐的用途

Also Published As

Publication number Publication date
CA3180351A1 (en) 2021-11-04
WO2021220250A1 (en) 2021-11-04
MX2022013021A (es) 2023-01-16
CN116390725A (zh) 2023-07-04
JP2023525981A (ja) 2023-06-20
AU2021265345A1 (en) 2022-12-08
KR20230035522A (ko) 2023-03-14
EP4142720A1 (en) 2023-03-08
US20230172921A1 (en) 2023-06-08
BR112022021951A2 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
US20110295365A1 (en) Anti-viral compositions and methods for administration
US12551469B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
ES2935834T3 (es) Métodos para tratar enfermedad de inmunodeficiencia
KR20240073720A (ko) Covid-19 질환을 치료하는 신규 조성물 및 방법
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
US11324750B2 (en) Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
IL297771A (en) Leriglitazone for treating lung inflammation and interstitial lung disease
US20230021647A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
KR20220166809A (ko) 급성 호흡곤란 증후군 및 바이러스 감염 치료를 위한 cxcr4 억제제
Tutak et al. A patient presenting with ARDS after COVID-19 vaccination: a COVID-19 case report
HK40096631A (zh) 用於治疗肺部炎症和间质性肺病的羟基吡格列酮
Magnani et al. FIV infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine 5′-triphosphate
EP4115885A1 (en) A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
RU2837859C1 (ru) Лечение коронавирусной инфекции
WO2025261398A1 (en) Methods for treating diseases caused by hiv infection
Haw et al. TLR7 promotes smoke-induced lung damage through the activity of mast cell tryptase
Ravindra Babu et al. Possible Mechanisms of Drugs Used in the Treatment of COVID-19: A Pharmacological Perspective
AU2024353056A1 (en) Brincidofovir for treatment of multiple sclerosis
Farne The prostaglandin D2 pathway in rhinovirus-induced asthma exacerbations
WO2021199003A1 (en) Oxidized lipids and treatment or prevention of inflammation or infectious disease caused by coronavirus infection
EA040061B1 (ru) Комбинация для лечения и ослабления rsv инфекции и фармацевтическая композиция на ее основе